Summary

Overview of key points and updates for 2018

  • Annual vaccination is the most important measure to prevent influenza and its complications.
  • Annual influenza vaccination is recommended for all persons ≥6 months of age.
  • For adults aged ≥65 years, in addition to the quadrivalent influenza vaccines (QIVs), two higher-immunogenicity
    trivalent influenza vaccine (TIV) formulations (one a ‘high-dose’ vaccine and another containing an adjuvant) are
    available and NIP-funded.
    • These TIVs are preferentially recommended over QIVs for adults aged ≥65 years. However, there is no
      preference for use between either of these two TIVs.
    • There is an increased likelihood of injection site reactions and systemic symptoms with these two TIVs, but no
      increase in the risk of severe adverse effects compared with standard TIVs.

Details

Publication Type
PDF
Topic
Research and Reports
Date Published
05 Mar 2018
Size
2 pages